Avosentan
Get a Quick Quote Now
Select Packaging
Product Description
Product
Avosentan
CAS
290815-26-8
Formula
C23H21N5O5S
Synonym
Avosentan, 290815-26-8, Ro 67-0565, SPP301, Avosentan [INN], SPP-301, L94KSX715K, 5-methylpyridine-2-sulfonic acid (6-methoxy-5-(2-methoxyphenoxy)-2-(pyridin-4-yl)pyrimidin-4-yl)amide, RO-67-0565, Ro670565, N-[6-methoxy-5-(2-methoxyphenoxy)-2-pyridin-4-ylpyrimidin-4-yl]-5-methylpyridine-2-sulfonamide, N-(6-Methoxy-5-(2-methoxyphenoxy)-2-(pyridin-4-yl)-pyrimidin-4-yl)-5-methylpyridine-2-sulfonamide, SPP 301, 2-Pyridinesulfonamide, N-(6-methoxy-5-(2-methoxyphenoxy)-2-(4-pyridinyl)-4-pyrimidinyl)-5-methyl-, UNII-L94KSX715K, N-(6-Methoxy-5-(2-methoxyphenoxy)-2-(pyridin-4-yl)pyrimidin-4-yl)-5-methylpyridine-2-sulfonamide, 2-Pyridinesulfonamide, N-[6-methoxy-5-(2-methoxyphenoxy)-2-(4-pyridinyl)-4-pyrimidinyl]-5-methyl-, GTPL8260, SCHEMBL2742679, CHEMBL3989834, DTXSID30183330, HMS3741G07, BCP28417, Avosentan,CAS:290815-26-8, BDBM50532577, CS-0625, NCGC00379058-01, AC-33590, HY-15195, MS-28915, Ro 67-0565; SPP-301, A-355, FT-0662342, J3.518.821E, F84811, L001646, Q27074636, 5-methyl-pyridine-2-sulfonic acid [6-methoxy-5-(2-methoxy-phenoxy)-2-pyridin-4-yl-pyrimidin-4-yl]-amide, 5-methyl-pyridine-2-sulfonic acid[6-methoxy-5-(2-methoxy-phenoxy)-2-pyridin-4-yl-pyrimidin-4-yl]-amide, N-[6-methoxy-5-(2-methoxyphenoxy)-2-pyridin-4-ylpyrimidin-4-yl]-5-methylpyridine-2-sulfonamide.
Typical Product Specifications
Assay/Purity
Typically NLT 98%
Notes
Avosentan is classified as an: Active Pharmaceutical Ingredient (API) / Pharmaceutical Intermediate
Class
Industry
Avosentan
Product Description
Product
Avosentan
CAS
290815-26-8
Formula
C23H21N5O5S
Synonym
Avosentan, 290815-26-8, Ro 67-0565, SPP301, Avosentan [INN], SPP-301, L94KSX715K, 5-methylpyridine-2-sulfonic acid (6-methoxy-5-(2-methoxyphenoxy)-2-(pyridin-4-yl)pyrimidin-4-yl)amide, RO-67-0565, Ro670565, N-[6-methoxy-5-(2-methoxyphenoxy)-2-pyridin-4-ylpyrimidin-4-yl]-5-methylpyridine-2-sulfonamide, N-(6-Methoxy-5-(2-methoxyphenoxy)-2-(pyridin-4-yl)-pyrimidin-4-yl)-5-methylpyridine-2-sulfonamide, SPP 301, 2-Pyridinesulfonamide, N-(6-methoxy-5-(2-methoxyphenoxy)-2-(4-pyridinyl)-4-pyrimidinyl)-5-methyl-, UNII-L94KSX715K, N-(6-Methoxy-5-(2-methoxyphenoxy)-2-(pyridin-4-yl)pyrimidin-4-yl)-5-methylpyridine-2-sulfonamide, 2-Pyridinesulfonamide, N-[6-methoxy-5-(2-methoxyphenoxy)-2-(4-pyridinyl)-4-pyrimidinyl]-5-methyl-, GTPL8260, SCHEMBL2742679, CHEMBL3989834, DTXSID30183330, HMS3741G07, BCP28417, Avosentan,CAS:290815-26-8, BDBM50532577, CS-0625, NCGC00379058-01, AC-33590, HY-15195, MS-28915, Ro 67-0565; SPP-301, A-355, FT-0662342, J3.518.821E, F84811, L001646, Q27074636, 5-methyl-pyridine-2-sulfonic acid [6-methoxy-5-(2-methoxy-phenoxy)-2-pyridin-4-yl-pyrimidin-4-yl]-amide, 5-methyl-pyridine-2-sulfonic acid[6-methoxy-5-(2-methoxy-phenoxy)-2-pyridin-4-yl-pyrimidin-4-yl]-amide, N-[6-methoxy-5-(2-methoxyphenoxy)-2-pyridin-4-ylpyrimidin-4-yl]-5-methylpyridine-2-sulfonamide.
Typical Product Specifications
Assay/Purity
Typically NLT 98%
Notes
Avosentan is classified as an: Active Pharmaceutical Ingredient (API) / Pharmaceutical Intermediate
Class
Industry
